[Disputable problems of the effect of sulfanilylurea derivatives in patients with diabetes mellitus and perspectives on their use].
Critical analysis of studies, realized by the University Group on diabetes mellitus program (UGDP), involving 12 colleges of the USA, was performed. A higher death rate due to cardiovascular pathology was manifested by patients with diabetes mellitus given tolbutamide. A possible restriction and/or prohibition of drugs of this series was discussed. The literature data and the authors' findings are presented, disproving the results, obtained by this Group. A wide use of sulfanilurea derivatives is recommended in the treatment of early stages of the disease, provided a stable 24 hours' normoglycemia is attained in patients with evident diabetes. The results obtained and the literature data allow the conclusion, that sulfanilurea derivatives exert an antiatherogenic effect under conditions of diabetes mellitus compensation.
D002271:Carbutamide / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007003:Hypoglycemia / Q000188:drug therapy; D008297:Male; D011236:Prediabetic State / Q000097:blood / Q000188:drug therapy*; D014044:Tolbutamide / Q000627:therapeutic use*
D014044:Tolbutamide; D002271:Carbutamide
Spornye voprosy ob éffekte proizvodnykh sul'fanilmocheviny u bol'nykh sakharnym diabetom i perspektivy ikh primeneniia.